Krishnendu Pal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4313902/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Zinc oxide nanoflowers make new blood vessels. Nanoscale, 2012, 4, 7861.	2.8	143
2	VEGF Exerts an Angiogenesis-Independent Function in Cancer Cells to Promote Their Malignant Progression. Cancer Research, 2012, 72, 3912-3918.	0.4	115
3	Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells <i>in vivo</i> . International Journal of Cancer, 2013, 132, 1201-1212.	2.3	92
4	Reactive Oxygen Species Driven Angiogenesis by Inorganic Nanorods. Nano Letters, 2011, 11, 4932-4938.	4.5	74
5	Synthetic heterovalent inhibitors targeting recognition E3 components of the N-end rule pathway. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 100-105.	3.3	70
6	GAIP Interacting Protein C-Terminus Regulates Autophagy and Exosome Biogenesis of Pancreatic Cancer through Metabolic Pathways. PLoS ONE, 2014, 9, e114409.	1.1	59
7	Inhibition of GSK-3 Induces Differentiation and Impaired Glucose Metabolism in Renal Cancer. Molecular Cancer Therapeutics, 2014, 13, 285-296.	1.9	56
8	BRAFV600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. Oncogene, 2019, 38, 6752-6766.	2.6	52
9	Non-metastatic 2 (NME2)-mediated suppression of lung cancer metastasis involves transcriptional regulation of key cell adhesion factor vinculin. Nucleic Acids Research, 2014, 42, 11589-11600.	6.5	47
10	Multifaceted peptide assisted one-pot synthesis of gold nanoparticles for plectin-1 targeted gemcitabine delivery in pancreatic cancer. Nanoscale, 2017, 9, 15622-15634.	2.8	46
11	A Lipid-Modified Estrogen Derivative that Treats Breast Cancer Independent of Estrogen Receptor Expression through Simultaneous Induction of Autophagy and Apoptosis. Molecular Cancer Research, 2011, 9, 364-374.	1.5	40
12	Development of multi-drug loaded PEGylated nanodiamonds to inhibit tumor growth and metastasis in genetically engineered mouse models of pancreatic cancer. Nanoscale, 2019, 11, 22006-22018.	2.8	40
13	Mutant <i>BRAF</i> Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. Molecular Cancer Therapeutics, 2016, 15, 3015-3027.	1.9	36
14	Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer. Oncotarget, 2017, 8, 85054-85067.	0.8	36
15	Selective Cancer Targeting via Aberrant Behavior of Cancer Cell-associated Glucocorticoid Receptor. Molecular Therapy, 2009, 17, 623-631.	3.7	32
16	Structureâ^'Activity Study To Develop Cationic Lipid-Conjugated Haloperidol Derivatives as a New Class of Anticancer Therapeutics. Journal of Medicinal Chemistry, 2011, 54, 2378-2390.	2.9	32
17	Tumor selective uptake of drug-nanodiamond complexes improves therapeutic outcome in pancreatic cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 18, 112-121.	1.7	31
18	Synchronous inhibition of mTOR and VEGF/NRP1 axis impedes tumor growth and metastasis in renal cancer. Npj Precision Oncology, 2019, 3, 31.	2.3	31

Krishnendu Pal

#	Article	IF	CITATIONS
19	<co-delivery a="" and="" everolimus="" formulation="" inhibits<br="" liposomal="" of="" tumor-targeted="" via="" vinorelbine="">tumor growth and metastasis in RCC. International Journal of Nanomedicine, 2019, Volume 14, 5109-5123.</co-delivery>	3.3	30
20	Inhibition of Endoglin–GIPC Interaction Inhibits Pancreatic Cancer Cell Growth. Molecular Cancer Therapeutics, 2014, 13, 2264-2275.	1.9	20
21	Glucocorticoid Receptor-Targeted Liposomal Codelivery of Lipophilic Drug and Anti-Hsp90 Gene: Strategy to Induce Drug-Sensitivity, EMT-Reversal, and Reduced Malignancy in Aggressive Tumors. Molecular Pharmaceutics, 2016, 13, 2507-2523.	2.3	20
22	Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells. BMC Cancer, 2016, 16, 336.	1.1	20
23	Molecular Inhibitor of QSOX1 Suppresses Tumor Growth <i>In Vivo</i> . Molecular Cancer Therapeutics, 2020, 19, 112-122.	1.9	17
24	Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma. Bioconjugate Chemistry, 2019, 30, 2703-2713.	1.8	12
25	Vascular Endothelial Growth Factor as an Immediate-Early Activator of Ultraviolet-Induced Skin Injury. Mayo Clinic Proceedings, 2022, 97, 154-164.	1.4	8
26	Targeted Dual Intervention-Oriented Drug-Encapsulated (DIODE) Nanoformulations for Improved Treatment of Pancreatic Cancer. Cancers, 2020, 12, 1189.	1.7	6
27	Dissecting VEGF-induced acute versus chronic vascular hyperpermeability: Essential roles of dimethylarginine dimethylaminohydrolase-1. IScience, 2021, 24, 103189.	1.9	3
28	Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer Journal of Clinical Oncology, 2017, 35, 603-603.	0.8	0
29	Abstract 705: Tumor intrinsic PD-L1 is mediated byBRAFV600Eand can regulate drug-induced apoptosis in human colon cancer. , 2019, , .		0